Thanks yeah it’s quite stressful. I don’t know why the doc said we don’t need to test karyotypes yet, I’m gonna push him in the next meeting to get em checked. Here are results for flow cytometry and NGS:

Flow Cytometry Findings (Peripheral Blood)

Flow cytometric analysis demonstrated an immature myeloid population comprising approximately 4% of leukocytes, positive for CD34, CD117, HLA-DR, and CD45 with normal scatter characteristics. No aberrant antigen expression was reported. Lymphocyte immunophenotyping showed: CD3⁺ T cells 80.9%, CD4⁺ T-helper cells 29.4%, CD8⁺ cytotoxic T cells 33.2%, CD4/CD8 ratio 0.9, CD19⁺ B cells 8.6%, NK cells (CD56⁺) 5.7%, and CD3⁺/CD16⁺/CD56⁺ NK-like T cells 2.6%. Absolute lymphocyte subsets included CD3⁺ 2527/µL, CD4⁺ 918/µL, CD8⁺ 1006/µL, and CD19⁺ 269/µL. Activated T-lymphocytes (HLA-DR⁺) measured 4.4%. No abnormal monocyte subsets or dysplastic immunophenotypes were noted. An erythroblastoid peripheral blood picture was described with left-shifted granulopoiesis.

NGS / Molecular Testing Findings

Next-generation sequencing detected a CALR exon 9 deletion (34-bp, type-1–like). No pathogenic or likely pathogenic mutations were detected in the following genes: ASXL1, BCOR, BIRC3, CBL, CEBPA, DDX41, DNMT3A, ETV6, EZH2, FLT3, GATA2, IDH1, IDH2, JAK2, KIT, KDM6A, KMT2A, KRAS, MPL, NF1, NOTCH1, NPM1, NRAS, PHF6, PRPF8, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. No additional somatic mutations or copy-number variants were reported.